Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STABILIZE Trial: Sequential Daratumumab Followed by Telitacicept for ABMR After Kidney Transplantation
NCT07902609Phase 2Active, not recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, telitacicept in antibody mediated rejection (AMR), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Started Jun 2026; status: active, not recruiting.
02
Drugs
daratumumabtelitacicept
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT07902609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902609.